Sleep Disorders

Following 13 weeks of treatment with once-nightly sodium oxybate, some patients in the 7.5 g and 9.0 g groups showed complete resolution of cataplexy attacks.

PUMAS significantly alleviated depression relative to controls whereas cognitive behavioral therapy-insomnia did not differ from either group.

Among patients with post-acute sequelae from COVID-19 infection, self-reported cognitive symptoms were correlated with severity of fatigue, anxiety, and depression, but not subjective sleep disturbance.

In a study of 59 individuals with obstructive sleep apnea, solriamfetol yielded cognitive improvements at post-dose time points throughout the day, along with improvements in Patient Global Impression of Severity.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of the American Academy of Sleep Medicine.

Neurofilament light, a biomarker elevated in neurodegeneration and dementia, was higher among poor sleepers with Pittsburgh Sleep Quality Index scores of less than 5.

Neurology News Network for the week ending June 2, 2023. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 2, 2023.

The medical director of SleepMed in South Carolina discussed the need for more overall awareness of poor sleep and the risk factors associated with worsened heart health. [WATCH TIME: 3 minutes]

Pitolisant, a therapy approved for patients with narcolepsy, is currently being assessed in 200 individuals with idiopathic hypersomnia, with change in excessive daytime sleepiness as the primary outcome.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Alzheimer disease and dementia.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 26, 2023.

Neurology experts discuss the unmet needs in narcolepsy treatment and share clinical pearls from their experiences.

Experts discuss sodium oxybate and antidepressants for treatment of cataplexy.

Experts discuss the efficacy and safety profile of solriamfetol for the treatment of narcolepsy.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is sleep and sleep disorders.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 19, 2023.

Anne Marie Morse, DO, FAASM, discusses the efficacy and safety profile of pitolisant for the treatment of narcolepsy.

Thomas E. Scammell, MD, provides an overview of the mechanism of action of pitolisant for the treatment of narcolepsy.

The director of the Sleep Disorders Center and staff in the Epilepsy Center at Cleveland Clinic provided perspective on the current state of sleep and epilepsy research, including the role of postical generalized EEG suppression as a biomarker for SUDEP.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is headache and migraine.

Positive associations between preexisting obstructive sleep apnea and probable post-acute sequelae among adults were attenuated but remained significant after adjusting for other comorbidities.